When P4A was originally conceived it was because Sophie Schmitz, Managing Partner, had noticed a clear disparity in the pharmaceutical world.
Companies would often chase quick profits from treatments that were not sustainable under a long-term healthcare system. Sophie also noticed that rare diseases and the patients desperate for effective treatments were woefully underrepresented. In 2015 Sophie set about addressing these two issues by creating P4A.
P4A have a clear commitment to the world of rare diseases.
We partner with our clients to achieve the following: